Barbara Ehrenreich, Why Your Child May Not Get a Swine Flu Shot Soon

Posted on

This week, the Obama White House released a very partial record of those who had visited since January 20, 2009. This it hailed as “transparency like you’ve never seen it before” and as the beginning of a new White House visitor transparency policy. Unfortunately, the policy applies mainly to post-September 15th visitors and has a caveat that, in time, could prove large enough to drive a Humvee through. As the White House website puts it, all names of visitors will be released after a lag of 90-120 days, “aside from a small group of appointments that cannot be disclosed because of national security imperatives or their necessarily confidential nature (such as a visit by a possible Supreme Court nominee).”

The version of the story that hit TV screens and most newspapers had to do with William Ayers, Jeremiah Wright, Michael Moore, and Michael Jordan, who were on the list, but weren’t actually William Ayers, Jeremiah Wright, Michael Moore, and Michael Jordan. Not the ones who come to your mind, anyway.

The secondary story was that Oprah Winfrey, George Clooney, Brad Pitt, and Bill Gates were exactly the Oprah Winfrey, George Clooney, Brad Pitt, and Bill Gates you’d imagine, and that in the last eight months a reasonable amount of star power had indeed passed through those well-guarded gates. Then there was labor leader Andrew Stern, fingered by the Wall Street Journal for his 22 visits.

And, oh yes, there were the others, too, even if they didn’t really cause much of a stir. On this already limited list of visitors, for instance, Wall Street was hardly missing-in-action, nor was big oil. Visiting “the people’s house” were Lloyd Blankfein, CEO of Goldman Sachs, who met a mere two times with the President and once with economic advisor Lawrence Summers; James Dimon, chief executive of J.P. Morgan Chase & Co., who made it in but six times, as well as Citigroup CEO Vikram Pandit; Rex Tillerson, chairman and chief executive of ExxonMobil Corp; David O’Reilly, CEO of Chevron; Maurice Greenberg, former head of AIG; and so on, including a striking crew of lobbyists. In other words, no big deal.

Now, me, I wouldn’t mind knowing whether on the unreleased visitors’ lists for these last months lurked Andrew Witty, CEO of GlaxoSmithKline, or Novartis CEO Daniel Vasella (or their lobbyists), not to speak of other Big Pharma types. Did they make it to the White House, and if so, how many times? I’m curious because Barbara Ehrenreich identifies their companies as the ones screwing up the production of the swine flu vaccine, and somehow they did manage to get a modest infusion of $2 billion from the Obama administration to do a less than magnificent job of this. I wonder just what deals might have been broached with them in the people’s name.

In the spirit of Ehrenreich’s remarkable new book, Bright-Sided: How the Relentless Promotion of Positive Thinking Has Undermined America — which I’ve recommended before — I’d like to exhibit a little positive thinking and hope that some enterprising reporter digs up this info for the rest of us, and soon. In the meantime, do check out Ehrenreich’s book (as well as the audio interview she did for TomDispatch to go with today’s piece). It admittedly won’t make you more optimistic, or even healthier, just a lot wiser and far more irritated. Tom


The Swine Flu Vaccine Screw-up

Optimism as a Public Health Problem
By Barbara Ehrenreich

If you can’t find any swine flu vaccine for your kids, it won’t be for a lack of positive thinking. In fact, the whole flu snafu is being blamed on “undue optimism” on the part of both the Obama administration and Big Pharma.

Optimism is supposed to be good for our health. According to the academic “positive psychologists,” as well as legions of unlicensed life coaches and inspirational speakers, optimism wards off common illnesses, contributes to recovery from cancer, and extends longevity. To its promoters, optimism is practically a miracle vaccine, so essential that we need to start inoculating Americans with it in the public schools — in the form of “optimism training.”

But optimism turns out to be less than salubrious when it comes to public health. In July, the federal government promised to have 160 million doses of H1N1 vaccine ready for distribution by the end of October. Instead, only 28 million doses are now ready to go, and optimism is the obvious culprit. “Road to Flu Vaccine Shortfall, Paved With Undue Optimism,” was the headline of a front page article in the October 26th New York Times. In the conventional spin, the vaccine shortage is now “threatening to undermine public confidence in government.” If the federal government couldn’t get this right, the pundits are already asking, how can we trust it with health reform?

But let’s stop a minute and also ask: Who really screwed up here — the government or private pharmaceutical companies, including GlaxoSmithKline, Novartis, and three others that had agreed to manufacture and deliver the vaccine by late fall? Last spring and summer, those companies gleefully gobbled up $2 billion worth of government contracts for vaccine production, promising to have every American, or at least every American child and pregnant woman, supplied with vaccine before trick-or-treating season began.

According to Health and Human Services Secretary Kathleen Sebelius, the government was misled by these companies, which failed to report manufacturing delays as they arose. Her department, she says, was “relying on the manufacturers to give us their numbers, and as soon as we got numbers we put them out to the public. It does appear now that those numbers were overly rosy.”

If, in fact, there’s a political parable here, it’s about Big Government’s sweetly trusting reliance on Big Business to safeguard the public health: Let the private insurance companies manage health financing; let profit-making hospital chains deliver health care; let Big Pharma provide safe and affordable medications. As it happens, though, all these entities have a priority that regularly overrides the public’s health, and that is, of course, profit — which has led insurance companies to function as “death panels,” excluding those who might ever need care, and for-profit hospitals to turn away the indigent, the pregnant, and the uninsured.

As for Big Pharma, the truth is that they’re just not all that into vaccines, traditionally preferring to manufacture drugs for such plagues as erectile dysfunction, social anxiety, and restless leg syndrome. Vaccines can be tricky and less than maximally profitable to manufacture. They go out of style with every microbial mutation, and usually it’s the government, rather than cunning direct-to-consumer commercials, that determines who gets them. So it should have been no surprise that Big Pharma approached the H1N1 problem ploddingly, using a 50-year old technology involving the production of the virus in chicken eggs, a method long since abandoned by China and the European Union.

Chicken eggs are fine for omelets, but they have quickly proved to be a poor growth medium for the viral “seed” strain used to make H1N1 vaccine. There are alternative “cell culture” methods that could produce the vaccine much faster, but in complete defiance of the conventional wisdom that private enterprise is always more innovative and resourceful than government, Big Pharma did not demand that they be made available for this year’s swine flu epidemic. Just for the record, those alternative methods have been developed with government funding, which is also the source of almost all our basic knowledge of viruses.

So, thanks to the drug companies, optimism has been about as effective in warding off H1N1 as amulets or fairy dust. Both the government and Big Pharma were indeed overly optimistic about the latter’s ability to supply the vaccine, leaving those of us who are involved in the care of small children with little to rely on but hope — hope that the epidemic will fade out on its own, hope that our loved ones have the luck to survive it.

And contrary to the claims of the positive psychologists, optimism itself is neither an elixir, nor a life-saving vaccine. Recent studies show that optimism — or positive feelings — do not affect recovery from a variety of cancers, including those of the breast, lungs, neck, and throat. Furthermore, the evidence that optimism prolongs life has turned out to be shaky at best: one study of nuns frequently cited as proof positive of optimism’s healthful effects turned out, in fact, only to show that nuns who wrote more eloquently about their vows in their early twenties tended to outlive those whose written statements were clunkier.

Are we ready to abandon faith-based medicine of both the individual and public health variety? Faith in private enterprise and the market has now left us open to a swine flu epidemic; faith alone — in the form of optimism or hope — does not kill viruses or cancer cells. On the public health front, we need to socialize vaccine manufacture as well as its distribution. Then, if the supply falls short, we can always impeach the president. On the individual front, there’s always soap and water.

Barbara Ehrenreich is the author of 16 books, including the bestsellers Nickel and Dimed and Bait and Switch. A frequent contributor to Harper’s and the Nation, she has also been a columnist at the New York Times and Time magazine. Her seventeenth book, Bright-Sided: How the Relentless Promotion of Positive Thinking Has Undermined America (Metropolitan Books), has just been published. An examination of recent studies of the medical ineffectiveness of positive thinking, mentioned in this essay, can be found in the book. To listen to the TomDispatch audio interview with Ehrenreich that accompanies this piece, click here.

Copyright 2009 Barbara Ehrenreich

Barbara Ehrenreich (1941-2022) was the author of 17 books, including the bestsellers Nickel and Dimed and Bait and Switch. A frequent contributor to Harper's and the Nation, she had also been a columnist at the New York Times and Time magazine.  To listen to the TomDispatch audio interview with Ehrenreich that accompanies this piece, click here.